Founded in 2011, Rebiotix is a privately held biotechnology company with deep roots in the development and commercialization of medical therapies. Board members have the wide-ranging education, skills, and on-the-job experiences needed to transform a promising idea into a profitable business.
Michael Berman is a medical device investor/entrepreneur working with a select group of high potential development and early commercial stage companies. He has founded/served on the board of several businesses, including Apnex, BeneChill, BridgePoint Medical, Lutonix, Velocimed, and others.
Prior to becoming an entrepreneur, he served as the President of Boston Scientific/Scimed. Under his leadership, worldwide sales in the interventional market increased from $300 million to $1.5 billion and the company fully integrated four acquired interventional cardiology businesses, invested more than $250 million in research and technology, and introduced more than 40 new products.
In 2010, Mr. Berman was inducted into the Minnesota Business Hall of Fame for his accomplishments as a Minnesota business leader.
He currently serves on the board of several emerging medical companies, including: BeneChill, ClearCut, Mazor Robotics, PharmaCentra, PulmOne and SoniVie. Collectively, his companies have raised more than $500 million during his board tenure.
Mr. Berman received a BS in industrial and labor relations and an MBA from Cornell University, Ithaca, NY.
Lee Jones is the founder, president, and chief executive officer of Rebiotix, a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome.
Lee has over 30 years of experience as a medical technology executive and entrepreneur in large and small companies and academia. With Rebiotix as her first foray into biotechnology, Lee is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy™ (MRT™) drug platform. The company’s first MRT is a biologic drug targeted at recurrent Clostridium difficile infection.
Before joining Rebiotix, Lee was the chief administrative officer of the Schulze Diabetes Institute at the University of Minnesota. She is also the former president and chief executive officer of Inlet Medical, a privately held medical device company that she grew to profitability prior to its sale to CooperSurgical in 2006. Prior to Inlet, she spent 14 years at Medtronic where she developed and commercialized several innovative products, including InterStim – a surgically implanted neurostimulation device for urinary incontinence that opened up new markets for the company.
Lee has served on several public and private boards and is currently on the board of Electromed Inc., on the University of Minnesota’s Office of Technology Commercialization advisory board, and on the board of Medical Alley Association, an industry association. She is a member of the Sofia Angel Investment Fund and is an advisor to several small companies.
Ms. Jones has a BS in Chemical Engineering from the University of Minnesota and an Executive Management degree from the Carlson School of Management at the University of Minnesota.
Erwin Kelen has been a full-time venture capitalist and angel investor for the past 25 years. He was a principal of the Quatris Fund, an early stage VC firm. He is the founder of Kelen Ventures, a business development and private investment firm. He has been involved in the formation, financing, growth and sale of many firms in the areas of technology, medical devices, and financial services.
Previously, he was the President and CEO of DataMyte Corporation, a factory automation hardware and software manufacturer. He was also Chairman and CEO of Electro-Craft Corporation, a manufacturer of DC servomotors and controls. Allen Bradley/Rockwell International acquired both companies.
Over the past 45 years, Mr. Kelen has served as director of several public and private companies, ranging from early stage development companies to firms listed on the New York Stock Exchange. He is also active in community affairs and serves on the Boards of the University of Minnesota Foundation and the Saint Paul Chamber Orchestra.
Mr. Kelen holds an undergraduate degree from the Technical University of Budapest, Hungary, and a Master’s degree in electrical engineering from the University of Minnesota, Minneapolis, MN.
William W. McGuire, MD, served as chairman and chief executive officer of the UnitedHealth Group from 1991 through 2007. Dr. McGuire focused on innovative programs that addressed a broad spectrum of health needs, issues, and constituencies. Under his leadership, the UnitedHealth Group emerged as the foremost healthcare provider in the US and enjoyed extraordinary growth – earnings per share compounded annually at 38% over his tenure.
Prior to joining the United Health Group, Dr. McGuire served as president of the Peak Health Plan in Colorado Springs, CO. He has practiced clinically in cardiopulmonary and critical care medicine and conducted basic research at Scripps Clinic and Research Foundation, La Jolla, CA.
Currently, Dr. McGuire continues to be involved in health-related issues surrounding access, affordability, appropriate use of health resources, outcomes, and overall wellness. He is also interested in basic medical research and is actively engaged in environmental research and perseveration efforts, educational initiatives, and the arts.
Dr. McGuire obtained his MD degree from the University of Texas Medical Branch in Galveston and received board certification in both internal medicine and in pulmonary medicine. He is an elected member of the Institute of Medicine of the National Academy of Sciences, and has served on the National Cancer Policy Board and the National Cancer Policy Forum.